Radiation Therapy for Soft Tissue Sarcomas

Similar documents
Radiotherapy Considerations in Extremity Sarcoma

What s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center

Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展

Multidisciplinary management of retroperitoneal sarcomas

INTRAOPERATIVE RADIATION THERAPY FOR RETROPERITONEAL SARCOMA

XXII Congresso Nazionale AIRO

Soft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee

Thoracic Recurrences. Soft tissue recurrence

14. Background. Sarcoma. Resectable extremity soft tissue sarcomas

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

Introduction ORIGINAL RESEARCH

Intraoperative Radiotherapy

Sacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician

Pediatric electron intraoperative radiotherapy: results and innovations

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

Collection of Recorded Radiotherapy Seminars

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING

Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015

3D CONFORMATIONAL INTERSTITIAL BRACHYTHERAPY PLANNING FOR SOFT TISSUE SARCOMA

INTRAOPERATIVE ELECTRON-BEAM THERAPY FOR PRIMARY AND RECURRENT RETROPERITONEAL SOFT-TISSUE SARCOMA

Index. Note: Page numbers of article titles are in boldface type.

Malcolm Mattes, MD Ajay Tejwani, MD, MPH New York Methodist Hospital

Ruolo dell imaging nella pianificazione del trattamento

Preoperative adjuvant radiotherapy

Malignant Peripheral Nerve Sheath Tumor post Wide Excision with Multiple Lung Metastases: the Role and Treatment Consideration of RT

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2

IAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June SOFT TISSUE SARCOMA (Non Rhabdomyosarcoma)

Adjuvant Radiotherapy for completely resected NSCLC

NEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah

Stereotactic radiotherapy

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed

Partial Breast Irradiation for Breast Conserving Therapy

Pancreatic Cancer and Radiation Therapy

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Partial Breast Irradiation using adaptive MRgRT

Proton or Photon RT for Retroperitoneal Sarcomas

TIP SHEET: TARGETED RADIATION FOR CHILDHOOD CANCER AND PROGRESS IN LOWERING TREATMENT COSTS AMONG RESEARCH PRESENTATIONS BY JOHNS HOPKINS SCIENTISTS

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

Clinical Case Conference

Protocol of Radiotherapy for Breast Cancer

Protons for Head and Neck Cancer. William M Mendenhall, M.D.

Radiation Therapy: From Fallacy to Science

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

Printed by Maria Chen on 3/11/2012 5:46:52 AM. For personal use only. Not approved for distribution. Copyright 2012 National Comprehensive Cancer

Correlation of Radiologic and Pathologic Response in Patients Receiving Neoadjuvant Radiotherapy for Soft Tissue Sarcoma

Radiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology

JAMES EWING, Endothelial origin. 14 yr Girl

How much colon should be resected?

Radiation Therapy for Thyroid Cancer. When is Radiation Therapy indicated in Thyroid Cancer of Follicular or Parafollicular Cell Origin?

Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT

External Beam Radiotherapy for Prostate Cancer

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas

Where are we with radiotherapy for biliary tract cancers?

BENEFIT APPLICATION BLUECARD/NATIONAL ACCOUNT ISSUES

Adjuvant radiation therapy of retroperitoneal sarcoma: the role of intraoperative radiotherapy (IORT)

FEP Medical Policy Manual

UCL. Rectum Adenocarcinoma. Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Trimodality Therapy for Muscle Invasive Bladder Cancer

Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL

Hypofractionated Radiotherapy for breast cancer: Updated evidence

Stereotactic ablative radiotherapy in early NSCLC and metastases

Insights into Thymic Epithelial Tumors: Radiation Therapy

High Risk Localized Prostate Cancer Treatment Should Start with RT

Opportunity for palliative care Research

Disclosure SBRT. SBRT for Spinal Metastases 5/2/2010. No conflicts of interest. Overview

Therapy of Non-Operable early stage NSCLC

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington

Why Choose Brachytherapy and Not External Beam RT or IORT?

CPT Codes: 77424, Last Review Date: July 2017 Guideline Number: NIA_CG_226 Last Revised Date: July 2017 Responsible Department:

Surgery for Breast Cancer

Disclosures. Overview 8/3/2016. SRS: Cranial and Spine

SBRT in early stage NSCLC

AMORE (Ablative surgery, MOulage technique brachytherapy and REconstruction) for childhood head and neck rhabdomyosarcoma Buwalda, J.

Radiotherapy in soft tissue sarcomas

Meta analysis in Rectal Cancer

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Radiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management

Collection of Recorded Radiotherapy Seminars

Selecting the Optimal Treatment for Brain Metastases

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer

Quality Variation and Clinical Impact in Head and Neck IMRT

Treatment of Recurrent Brain Metastases

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

What is an Adequate Lumpectomy Margin in 2018?

The role of radiotherapy in the management of localized soft tissue sarcomas

9.5. CONVENTIONAL RADIOTHERAPY TECHNIQUE FOR TREATING THYROID CANCER

Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015

Number: Policy *Please see amendment for Pennsylvania Medicaid at the. Last Review 08/25/2016 Effective: 03/17/2006 Next Review: 08/24/2017

Radiotherapy Physics and Equipment

American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy

Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience

EVIDENCE BASED MANAGEMENT FOR SOFT TISSUE SARCOMA

New Technologies for the Radiotherapy of Prostate Cancer

Transcription:

Radiation Therapy for Soft Tissue Sarcomas Alexander R. Gottschalk, MD, PhD Assistant Professor, Radiation Oncology University of California, San Francisco 1/25/08

NCI: limb salvage vs. amputation 43 patients randomized 2:1 to WLE + XRT or amputation Local recurrence 4/27 WLE vs 0/16 amp (p=0.06) Positive margins correlated with local recurrence No difference in overall survival or DFS Rosenberg Ann Surg. 1982; 196(3):305-15.

NCI: limb salvage vs. amputation QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Rosenberg Ann Surg. 1982; 196(3):305-15.

NCI: XRT vs No XRT 91 patients high-grade: WLE (44) vs WLE + XRT (47) All received adjuvant chemotherapy 50 patient low-grade: WLE (24) vs WLE + XRT (26) Median f/u 9-10 yrs Local recurrence High-grade: 17/44 (39%) WLE vs 1/47 (2%) WLE + XRT (p=0.0028) Low-grade: 8/24 (33%) WLE vs 1/26 (4%) WLE + XRT (p=0.016) No difference in overall survival or DFS Yang JCO 1998; 16:197-203.

NCI: XRT vs No XRT QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Yang JCO 1998; 16:197-203.

MSKCC: brachy vs No brachy 164 patients: WLE (86) vs WLE + brachy (78) Median f/u 76 months Local control at 5 years WLE 69% vs WLE + XRT 82% (p=0.04) High-grade: WLE: 66% vs WLE + XRT 89% (p=0.0025) Low-grade: WLE: 76% vs WLE + XRT 83% (p=0.6) No difference in overall survival or DFS Pisters JCO 1996; 14:859-868

MSKCC: brachy vs No brachy QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Pisters JCO 1996; 14:859-868

QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

NCIC: pre-op vs post-op XRT 190 patients randomized: pre-op 50 Gy (94) vs post-op 66 Gy (96) Median f/u 76 months Wound complications: pre-op (35%) vs post-op (17%) p=0.01 No difference in local control Grade 2 or higher fibrosis Pre-op 31% vs post-op 48% (p=0.07) Edema Pre-op 15%% vs post-op 23% (p=ns) Joint stiffness Pre-op 18%% vs post-op 23%% (p=ns) O Sullivan Lancet 2002; 359:2235 Davis Radiother Oncol 2005; 75:48

Local Control After Radiation QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Zagars Cancer 2003; 97:2530

Local Control After Radiation QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Zagars Cancer 2003; 97:2530

Local Control After Radiation QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Zagars Cancer 2003; 97:2530

Local Control After Radiation QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Zagars Cancer 2003; 97:2530

Radiation Therapy Techniques Rigid immobilization Spare > 1 cm strip of skin To prevent edema Minimize dose to whole bone (< 50 Gy) Do not cross joint space Bolus scar unless tangential beams used CT planning essential Use beam modifiers Wedges Filed-within-field Use 6MV for extremities

Radiation Therapy Techniques Pre-op Gross tumor plus 5 cm proximal and distal 2 cm radial (except where near bone or crossing joint space) Cone down (if used) GTV plus 2-3 cm all around

Radiation Therapy Techniques Post-op First course - larger volume of: All tissue handled (tumor bed, drain, scar) + 2cm Tumor bed + 5 cm proximal/distal and 2 cm radial (except where near bone or crossing joint space) Cone down #1 Tumor bed + 2-3 cm all around Cone cone #2 (if given) Tumor bed + 1-2 cm margin all around

Radiation Therapy Dose Pre-operative XRT: Pre-op volume to 50 Gy Post-op boost (positive margins) 16-20 Gy Post-operative XRT First course 45-50 Gy Cone down #1 10-15 Gy Cone down #2 6-10 Gy Total dose: 60 Gy (- margins) 66 Gy (+ margins) 70+ Gy (gross disease)

Radiation Therapy Dose Positive margins Recommend 66 Gy QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Delaney IJROBP 2007

Radiation therapy techniques QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

Radiation therapy techniques QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

Field-within-field

Complications Impaired wound healing 15-40% Edema 20% Fibrosis, decreased ROM 20% Bone fracture 2-10% Peripheral nerve injury 1-10%

Complications: Lower Extremities Acute Would complications 27% Pre-op (34%) vs post-op 16% p<0.001 Size > 5 cm (31%) vs < 5 cm (17%) p=0.04 Chronic limb complications 13% Groin/thigh (16%) vs other sites (4%) p=.008 Prior acute wound complication Yes (20%) vs none (10%) p=.003 Dose > 60 Gy (18%) vs < 60 Gy (9%) p=0.04 Bone fracture 1.2% Cannon Cancer 2006

Complications: Bone Fracture 205 patients with STS of thigh Treated with surgery + XRT 9 patients (0.04%) developed femur fracture High-risk patients included: Periosteal stripping Female chemotherapy Lin Cancer 1998

Complications: Bone Fracture 364 patients with STS of lower extremity Treated with surgery + XRT 4% fractures at 5 years High-dose (60-66 Gy) 7% Low dose (50 Gy) 0.6% p=.007 Female 6% Male 2% p=.02 Age > 55 years 7% Age < 55 years 1% p=.004 Holt J Bone Joint Surg 2005, 87: 315

How can we decrease toxicity and maintain excellent local control? Answer:? Intensity Modulated Radiation Therapy (IMRT) Intra-Operative Radiation Therapy (IORT)

IMRT for STS Goals: Maintain excellent local control Reduce morbidity Edema Joint stiffness Wound complications fractures

Is IMRT better than 3D? Comparison of 3D vs IMRT plans for 10 cases of STS close to femur Definitions CTV = GTV + 1.5 cm radially, or at bone interface CTV = GTV + 5-10 cm sup/inf PTV = CTV + 5mm Hong IJROBP 2004

IMRT for STS QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

IMRT vs 3D for STS QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

IMRT

IMRT for STS Appeal: Spare more normal tissue Reduce morbidity Concerns: Reduction in local control Marginal misses Potential increased risk of 2nd malignancies Due to increase volume receiving low dose Other unforeseen morbidities

NCI: IORT for Retroperitoneal Sarcomas N=35 15 IORT 20 no IORT Median f/u 8 years R a n d o m i z e Surgery + 20 Gy IORT + post-op XRT (35-40 Gy) Surgery + post-op XRT (50-55 Gy)

NCI: Retroperitoneal Sarcomas Overall survival Local recurrence Peripheral neuropathy + IORT No IORT 45 m 52 m 6/15 16/20 9/15 1/20 Peripheral neuropathy developed in IORT patients only when large IORT Fields were used to cover tumor beds in the area of the sacral nerve plexis Sindelar et al. Arch Surg 1993, 128:402

NCI: Retroperitoneal Sarcomas QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. Sindelar et al. Arch Surg 1993, 128:402

IORT for extremity sarcomas German retrospective review of 153 patients Median IORT dose 15 Gy Mean EBRT dose 43 Gy (40-50.4 Gy) Median f/u 33 m Local control (5 yr) 78% Acute grade 2-4 toxicity 23% Late grade 2-4 toxicity 17% Oertel et al. IJROBP 2006, 64:1416

IORT for extremity sarcomas: UCSF experience Identified 56 consecutive patients who underwent limb-sparing resection by a single orthopedic oncologist followed by IORT between 1998 and 2007. Indications for IORT included: tumors whose proximity to critical structures resulted in the expectation of close or microscopically positive surgical margins, and recurrent tumors within previously irradiated fields. The median IORT dose was 12.5 Gy (range 10-17.9 Gy). Tsuji abstract ASTRO 2007

IORT for extremity sarcomas: UCSF experience Median follow up of 22 months 2- and 5-year estimated rates of local control were 79% (95% CI 62-89%) and 76% (58-87%), respectively; Distant metastasis-free survival were 75% (59-86%) and 68% (50-81%), respectively; Overall survival were 85% (69-93%) and 70% (50-83%), respectively. Tsuji abstract ASTRO 2007

IORT for extremity sarcomas: UCSF experience The two-year local control rate for tumors with positive or close margins ( 1 mm) was 76%, compared with 83% for margins > 1 mm. The two-year local control rate for patients who did not receive adjuvant EBRT was 65%, and 87% for those who did (median dose 56 Gy). The two-year local control rate was 91% versus 47% for primary versus recurrent tumors (p=0.01). Patients with primary tumors had a two-year local control rate of 100% if the margin was >1mm, and 83% for positive/close margins. Eight patients (14.3%) developed grade 3 wound healing complications; 7 of these patients had received adjuvant EBRT. Tsuji abstract ASTRO 2007

IORT for extremity sarcomas: Conclusions: UCSF experience IORT offers a viable method of delivering local therapy Excellent local control in primary tumors (91%) 100% LC in primary tumors with margins > 1mm 83 % LC in primary tumors with close/positive margins Reduced dose of post-op XRT (median dose 56 Gy) May translate to less toxicity Low wound healing complications (14%) Good local control for recurrent tumors in previously radiated fields (47%) Tsuji abstract ASTRO 2007

IORT for extremity sarcomas: UCSF experience Doses IORT 12-15 Gy Post-op XRT - margins: 50 Gy to large field Expected + margin (in IORT field) 50 Gy to large field + 6-10 Gy boost: total dose 56-60 Gy Unexpected + margin (not in IORT field) 50 Gy to large field + 16 Gy boost: total dose 66 Gy

Surgery for lung metastases QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

Radiosurgery for lung metastases QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

Radiosurgery for lung metastases

Radiosurgery for lung metastases QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.